ALXO Stock Forecast & Price Target

ALX Oncology Holdings Inc. is advancing its clinical-stage immuno-oncology pipeline, highlighted by the CD47 blocker evorpacept and the recently introduced EGFR-targeting ADC ALX2004, which has demonstrated significant anti-tumor activity across various cancer models. The company's strategic focus on combining evorpacept with established antibodies, such as trastuzumab and zanidatamab, is supported by promising data from clinical trials, suggesting strong potential for efficacy in treating HER2-positive cancers. Additionally, management's optimistic outlook regarding the ongoing and future trial phases strengthens the likelihood of successful outcomes, which could enhance shareholder value and position the company favorably within the oncology market.

ALX Oncology Holdings Inc. has faced challenges in its financial outlook, reflecting a complete lack of revenues in the fourth quarter of 2024, which aligns with consensus expectations yet underscores an ongoing financial struggle. The company reported a net loss of $0.55 per share, which, while slightly better than the consensus estimate of $0.67, still indicates significant financial pressure during this clinical stage. Additionally, the risk of FDA rejection for accelerated approval paths in key cancer treatments, combined with the delayed emergence of crucial clinical data until 2026, raises further concerns about the company's ability to generate positive momentum in the near future.